Analysis of bacterial vaginosis, the vaginal microbiome, and sexually transmitted infections following the provision of menstrual cups in Kenyan schools: Results of a nested study within a cluster randomized controlled trial.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
07 2023
Historique:
received: 04 11 2022
accepted: 07 06 2023
medline: 27 7 2023
pubmed: 25 7 2023
entrez: 25 7 2023
Statut: epublish

Résumé

Nonhygienic products for managing menstruation are reported to cause reproductive tract infections. Menstrual cups are a potential solution. We assessed whether menstrual cups would reduce bacterial vaginosis (BV), vaginal microbiome (VMB), and sexually transmitted infections (STIs) as studies have not evaluated this. A cluster randomized controlled trial was performed in 96 Kenyan secondary schools, randomized (1:1:1:1) to control, menstrual cup, cash transfer, or menstrual cup plus cash transfer. This substudy assessing the impact of menstrual cups on BV, VMB, and STIs, included 6 schools from the control (3) and menstrual cup only (3) groups, both receiving BV and STI testing and treatment at each visit. Self-collected vaginal swabs were used to measure VMB (16S rRNA gene amplicon sequencing), BV (Nugent score), and STIs. STIs were a composite of Chlamydia trachomatis and Neisseria gonorrhoeae (nucleic acid amplification test) and Trichomonas vaginalis (rapid immunochromatographic assay). Participants were not masked and were followed for 30 months. The primary outcome was diagnosis of BV; secondary outcomes were VMB and STIs. Intention-to-treat blinded analyses used mixed effects generalized linear regressions, with random effects term for school. The study was conducted between May 2, 2018, and February 7, 2021. A total of 436 participants were included: 213 cup, 223 control. There were 289 BV diagnoses: 162 among control participants and 127 among intervention participants (odds ratio 0.76 [95% CI 0.59 to 0.98]; p = 0.038). The occurrence of Lactobacillus crispatus-dominated VMB was higher among cup group participants (odds ratio 1.37 [95% CI 1.06 to 1.75]), as was the mean relative abundance of L. crispatus (3.95% [95% CI 1.92 to 5.99]). There was no effect of intervention on STIs (relative risk 0.82 [95% CI 0.50 to 1.35]). The primary limitations of this study were insufficient power for subgroup analyses, and generalizability of findings to nonschool and other global settings. Menstrual cups with BV and STI testing and treatment benefitted adolescent schoolgirls through lower occurrence of BV and higher L. crispatus compared with only BV and STI testing and treatment during the 30 months of a cluster randomized menstrual cup intervention. ClinicalTrials.gov NCT03051789.

Sections du résumé

BACKGROUND
Nonhygienic products for managing menstruation are reported to cause reproductive tract infections. Menstrual cups are a potential solution. We assessed whether menstrual cups would reduce bacterial vaginosis (BV), vaginal microbiome (VMB), and sexually transmitted infections (STIs) as studies have not evaluated this.
METHODS AND FINDINGS
A cluster randomized controlled trial was performed in 96 Kenyan secondary schools, randomized (1:1:1:1) to control, menstrual cup, cash transfer, or menstrual cup plus cash transfer. This substudy assessing the impact of menstrual cups on BV, VMB, and STIs, included 6 schools from the control (3) and menstrual cup only (3) groups, both receiving BV and STI testing and treatment at each visit. Self-collected vaginal swabs were used to measure VMB (16S rRNA gene amplicon sequencing), BV (Nugent score), and STIs. STIs were a composite of Chlamydia trachomatis and Neisseria gonorrhoeae (nucleic acid amplification test) and Trichomonas vaginalis (rapid immunochromatographic assay). Participants were not masked and were followed for 30 months. The primary outcome was diagnosis of BV; secondary outcomes were VMB and STIs. Intention-to-treat blinded analyses used mixed effects generalized linear regressions, with random effects term for school. The study was conducted between May 2, 2018, and February 7, 2021. A total of 436 participants were included: 213 cup, 223 control. There were 289 BV diagnoses: 162 among control participants and 127 among intervention participants (odds ratio 0.76 [95% CI 0.59 to 0.98]; p = 0.038). The occurrence of Lactobacillus crispatus-dominated VMB was higher among cup group participants (odds ratio 1.37 [95% CI 1.06 to 1.75]), as was the mean relative abundance of L. crispatus (3.95% [95% CI 1.92 to 5.99]). There was no effect of intervention on STIs (relative risk 0.82 [95% CI 0.50 to 1.35]). The primary limitations of this study were insufficient power for subgroup analyses, and generalizability of findings to nonschool and other global settings.
CONCLUSIONS
Menstrual cups with BV and STI testing and treatment benefitted adolescent schoolgirls through lower occurrence of BV and higher L. crispatus compared with only BV and STI testing and treatment during the 30 months of a cluster randomized menstrual cup intervention.
TRIAL REGISTRATION
ClinicalTrials.gov NCT03051789.

Identifiants

pubmed: 37490459
doi: 10.1371/journal.pmed.1004258
pii: PMEDICINE-D-22-03601
pmc: PMC10368270
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Banques de données

ClinicalTrials.gov
['NCT03051789']

Types de publication

Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1004258

Subventions

Organisme : NICHD NIH HHS
ID : R01 HD093780
Pays : United States
Organisme : Medical Research Council
ID : MR/N006046/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright: © 2023 Mehta et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet Public Health. 2019 Aug;4(8):e376-e393
pubmed: 31324419
J Int AIDS Soc. 2022 Jul;25(7):e25962
pubmed: 35822945
Sex Transm Infect. 2005 Jun;81(3):242-7
pubmed: 15923295
Int J Environ Res Public Health. 2018 Aug 07;15(8):
pubmed: 30087298
Soc Indic Res. 2017;133(3):1047-1073
pubmed: 28931968
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
AIDS. 2008 Jul 31;22(12):1493-501
pubmed: 18614873
PLoS One. 2018 Dec 7;13(12):e0208167
pubmed: 30532210
Bioinformatics. 2014 Mar 1;30(5):614-20
pubmed: 24142950
Clin Infect Dis. 2014 Jul 15;59(2):193-205
pubmed: 24729507
Microbiome. 2020 Nov 23;8(1):166
pubmed: 33228810
J Womens Health (Larchmt). 2011 Feb;20(2):303-11
pubmed: 21194348
J Infect Dis. 2014 Aug 15;210(4):593-6
pubmed: 24596283
Front Cell Infect Microbiol. 2021 Sep 21;11:716537
pubmed: 34621690
Int J STD AIDS. 2018 Nov;29(13):1258-1272
pubmed: 30049258
Am J Obstet Gynecol. 2019 Apr;220(4):324-335
pubmed: 30447213
J Infect Dis. 2006 Jun 1;193(11):1478-86
pubmed: 16652274
Sci Transl Med. 2012 May 2;4(132):132ra52
pubmed: 22553250
J Womens Health (Larchmt). 2015 Oct;24(10):801-11
pubmed: 26296186
Methods Mol Biol. 2018;1783:149-169
pubmed: 29767361
Clin Infect Dis. 2000 Jun;30(6):901-7
pubmed: 10852812
BMJ Open. 2016 Nov 23;6(11):e013229
pubmed: 27881530
Front Med (Lausanne). 2018 Jun 13;5:181
pubmed: 29951482
Curr Opin Infect Dis. 2020 Feb;33(1):59-65
pubmed: 31789672
J Clin Microbiol. 1991 Feb;29(2):297-301
pubmed: 1706728
Int J Health Sci (Qassim). 2018 Sep-Oct;12(5):90-100
pubmed: 30202413
BMC Public Health. 2019 Oct 21;19(1):1317
pubmed: 31638946
Sex Transm Dis. 2021 Oct 1;48(10):766-772
pubmed: 33859147
PLoS Med. 2018 Feb 27;15(2):e1002511
pubmed: 29485986
mSystems. 2019 Feb 19;4(1):
pubmed: 30801027
Womens Health Rep (New Rochelle). 2022 Sep 15;3(1):773-784
pubmed: 36185073
J Basic Microbiol. 2001;41(1):37-43
pubmed: 11314245
J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):17-25
pubmed: 35972852

Auteurs

Supriya D Mehta (SD)

Division of Infectious Disease Medicine, Rush University College of Medicine, Chicago, Illinois, United States of America.
Division of Epidemiology & Biostatistics, University of Illinois Chicago School of Public Health, Chicago, Illinois, United States of America.

Garazi Zulaika (G)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Walter Agingu (W)

Nyanza Reproductive Health Society, Kisumu, Kenya.

Elizabeth Nyothach (E)

Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.

Runa Bhaumik (R)

Division of Epidemiology & Biostatistics, University of Illinois Chicago School of Public Health, Chicago, Illinois, United States of America.

Stefan J Green (SJ)

Department of Internal Medicine and Genomics and Microbiome Core Facility, Rush University, Chicago, Illinois, United States of America.

Anna Maria van Eijk (AM)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Daniel Kwaro (D)

Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.

Fredrick Otieno (F)

Nyanza Reproductive Health Society, Kisumu, Kenya.

Penelope Phillips-Howard (P)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH